ZG heads into the week with a notable analyst capitulation fresh on the tape and short interest that has eased from its June peak but remains elevated — a combination that keeps the stock's discount to consensus unusually wide.
The clearest development this week is RBC Capital's target cut. Brad Erickson, who reiterated Outperform as recently as May 21, slashed his price objective from $95 to $70 on June 10 — a 26% reduction while holding his positive rating. That move matters because it follows a wave of post-earnings cuts in early May, when Barclays, Wells Fargo, Piper Sandler, Keybanc, Mizuho, and Citigroup all trimmed targets. The Street remains broadly constructive on direction — most active ratings are Outperform, Overweight, or Buy — but the consensus mean target has been dragged down to $64, still nearly double the current price of $35.83. That gap is less a bullish catalyst and more a reflection of how aggressively targets have been reset downward without a corresponding re-rating of the underlying.
Short interest has pulled back slightly from where it was documented a week ago, but the broader trend is intact. At 7.2% of free float — down from 7.4% last week and well off the 9.2% peak flagged on May 27 — shorts have trimmed around the stock's 3% bounce on June 9 but have not meaningfully exited. Over the past month, short interest is still up 16%. The borrow market continues to offer no friction: availability runs at 309%, meaning roughly three shares are available for every one currently borrowed, and the cost to borrow is just 0.53%. Shorts face no squeeze pressure and can add positions cheaply. The ORTEX short score has eased slightly to 55.9 from the 57.4 high touched on June 4, but the week-long range is narrow — consistent with a position that is consolidating rather than unwinding.
Options are similarly unremarkable. The put/call ratio at 0.70 is effectively in line with its 20-day average of 0.70, with a z-score near zero. There is no unusual defensive or speculative skew at this level — options traders are neither loading up on downside protection nor pressing calls. Relative to the 52-week PCR range of 0.05 to 2.92, the current reading is among the most neutral on record, suggesting that derivatives markets are sitting on their hands ahead of the next earnings event, which lands on August 5.
The institutional picture adds some nuance. Capital Research added over 6.4 million shares as of late May — a notable accumulation that makes them the third-largest holder at 7.6% of shares. Independent Franchise Partners also added roughly 3 million shares in Q1. Against that, Caledonia, the largest holder at 16.3%, trimmed slightly. The co-founder and chairman Lloyd Frink remains a holder of 2.7% with minimal recent activity. Insider data is stale — the most recent trade on file dates from November 2024 — so there is no fresh signal from that direction.
The bull case rests on EPS momentum: the 30-day and 90-day forward earnings revision scores rank in the 87th and 79th percentiles respectively, and the 12-month forward EPS growth estimate ranks in the 78th percentile. The bear case is that the stock is stuck: down 14.6% over the past month, trading at $35.83 against a consensus target that even after all the cuts still implies a double, and with short sellers who keep rebuilding every time the stock bounces. The EV/EBITDA multiple at 8.7x has crept higher on the 30-day view, while the P/E at 13.6x has compressed — reflecting the tug between improving earnings estimates and a stock price that keeps drifting lower. Relative to peers, CBRE and JLL both gained over 3% this week; ZG finished the week down 2%.
The August 5 earnings date is now the next focal point — with the short position stable, the borrow market loose, and the Street freshly cutting targets, how management frames the housing demand outlook will determine whether the current short base grows further or begins a more durable reduction.
See the live data behind this article on ORTEX.
Open ZG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
